Drug Search Results
More Filters [+]

Nerispirdine

Alternative Names: nerispirdine
Latest Update: 2016-02-26
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT6 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nerispirdine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Sclerosis|Optic Neuritis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-001999-67

P2

Completed

Multiple Sclerosis

2010-03-02

DRI10566

P2

Completed

Multiple Sclerosis

2010-03-01

ACT10573

P2

Completed

Multiple Sclerosis|Optic Neuritis

2009-06-01

Recent News Events

Date

Type

Title